Gossamer Bio (GOSS) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Gossamer Bio (GOSS) over the past year, losing 15.0% versus a loss of 95.5%. Over five years, TLPH leads with a -94.7% price change compared with -99.2% for GOSS. Gossamer Bio is the larger company by market cap ($56.9 million vs $56.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | TLPH |
|---|---|---|
| Share price | $9.31 | $1.08 |
| Market cap | $56.94M | $56.06M |
| 1-day change | -5.77% | 0.00% |
| YTD return | -96.25% | -5.26% |
| 1-year return | -95.45% | -14.96% |
| 5-year return | -99.17% | -94.71% |
| EPS (TTM) | $-52.80 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $309.60 | $1.57 |
| 52-week low | $9.12 | $0.69 |
| Distance from 52-week high | -96.99% | -31.21% |
| Analyst consensus | buy | none |
| Avg. price target upside | +785.93% | +189.81% |
| Average volume | 378.37K | 222.56K |
| Shares outstanding | 6.12M | 51.91M |
| Employees | 161 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed GOSS by 80.5 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
GOSS vs TLPH FAQ
Which is bigger, Gossamer Bio or Talphera?
Gossamer Bio (GOSS) is larger, with a market capitalization of $56.94M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, GOSS or TLPH?
TLPH returned -14.96% over the past 12 months, compared with -95.45% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.